CSIMarket Company Name, Ticker, Competitors, else..
 

Tuhura Biosciences Inc   (NASDAQ: HURA)

Tuhura Biosciences Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

HURA Sales vs. its Competitors Q2 2026


Comparing the current results to its competitors, Tuhura Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 35.19 %, recorded in the same quarter.

• List of HURA Competitors





Revenue Growth Comparisons




Net Income Comparison

Tuhura Biosciences Inc recorded a net loss, as well as most of its competitors.

<<  HURA Stock Performance Comparisons


Tuhura Biosciences Inc 's Comment on Competition and Industry Peers


The biotechnology industry faces uncertainties and challenges regarding patent protection, including risks that patents may be challenged, circumvented, or invalidated. Companies must avoid infringing on third-party proprietary rights, which may necessitate modifying development or commercial strategies, obtaining licenses, or discontinuing certain activities. Orphan drug exclusivity provides a seven-year period during which approval of competing products is blocked unless clinical superiority is demonstrated. Additionally, some U.S. patents may qualify for limited patent term extensions of up to five years, depending on FDA approval details.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Tuhura Biosciences Inc




Zymeworks Inc
Share Performance



+0.79%
This Year
Zymeworks Inc
Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,958.338 mill. $ 37.127 mill. $ -149.992 mill.


Phio Pharmaceuticals Corp
Share Performance



-1.89%
This Quarter
Phio Pharmaceuticals Corp
Profile

Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.

More about Phio Pharmaceuticals Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 12.082 mill. $ - mill. $ -12.904 mill.


Phathom Pharmaceuticals Inc
Share Performance



-8.74%
Over The Past 5 Days
Phathom Pharmaceuticals Inc
Profile

Phathom Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing treatments for gastrointestinal diseases. Their business model involves advancing their pipeline of drug candidates through research and development, and seeking regulatory approval for commercialization. By strategically targeting unmet medical needs in the gastrointestinal space, Phathom Pharmaceuticals aims to provide innovative solutions to improve patient outcomes.

More about Phathom Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 726.087 mill. $ 239.663 mill. $ -99.072 mill.


Oramed Pharmaceuticals Inc
Share Performance



+102.16%
One Year
Oramed Pharmaceuticals Inc
Profile

Oramed Pharmaceuticals Inc. is a biopharmaceutical company with a business model focused on developing innovative oral drug delivery solutions.

More about Oramed Pharmaceuticals Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 199.331 mill. $ - mill. $ 174.864 mill.


Nextcure Inc
Share Performance



+20.36%
One Year
Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 35.150 mill. $ - mill. $ -42.748 mill.

45 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Tuhura Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tuhura Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.